DR. ERIC LEWIN ALTSCHULER, M.D.
Physical Therapy at 1 Ave, New York, NY
License number
New York MD451984
Category
Medical Practice
Type
Physical Medicine & Rehabilitation
License number
New York 25MA07902500
Category
Medical Practice
Type
Physical Medicine & Rehabilitation
License number
New York 227788
Category
Medical Practice
Type
Physical Medicine & Rehabilitation
Address
Address
1901 1St Ave, New York, NY 10029
Phone
(212) 423-6448
(212) 423-6326 (Fax)
(646) 784-3543
(212) 423-6326 (Fax)
(646) 784-3543
Personal information
See more information about ERIC LEWIN ALTSCHULER at radaris.comName
Address
Phone
1139 Prospect Ave, Brooklyn, NY 11218
149 Bidwell Ave, Staten Island, NY 10314
45 Sutton Pl S APT 8I, New York, NY 10022
149 Bidwell Ave, Staten Island, NY 10314
1139 Prospect Ave, Brooklyn, NY 11218
Professional information
See more information about ERIC LEWIN ALTSCHULER at trustoria.com
Methods For Treating Crohn's And Other Tnf Associated Diseases
Methods For Treating Crohn's And Other Tnf Associated Diseases
US Patent:
2004000, Jan 1, 2004
Filed:
Sep 14, 2002
Appl. No.:
10/244037
Inventors:
Eric Altschuler - New York NY, US
International Classification:
A61K031/137
US Classification:
514/649000
Abstract:
A new method employing a known compound, bupropion hydrochloride (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride, and its analogues, in a new use for the treatment of TNF-related disorders is described.
Methods Of Modulating Tnf Using Bupropion
Methods Of Modulating Tnf Using Bupropion
US Patent:
2006017, Aug 3, 2006
Filed:
Dec 1, 2005
Appl. No.:
11/291730
Inventors:
Eric Altschuler - New York NY, US
Richard Kast - Burlington VT, US
Richard Kast - Burlington VT, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/137
US Classification:
514649000
Abstract:
A new method employing a known compound, bupropion hydrochloride (.±.)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride, and its analogues, in a new use for the treatment of TNF-related disorders is described.